+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Novel Drug Reconstitution Systems Market by Type of Container, Fabrication Material, Physical State of Drug in Syringe and Cartridge, Physical State of Drug in Infusion Bag, Volume of Container, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • ID: 5470970
  • Report
  • September 2021
  • Region: Global
  • 325 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 3M Innovative Properties
  • Baxter
  • EMD Serono
  • JW Chemi Town
  • Pfizer
  • Strongbridge Biopharma

Overview

Over the last few years, numerous biologics and small molecule drugs have made their way to the market. Most of these biologic products are not stable as liquid formulations, and tend to lose efficacy with alterations in their pharmacokinetic and pharmacodynamic properties, thereby, making it difficult to preserve them for longer period of time. In order to achieve longer shelf life, lyophilization has emerged as the preferred choice for making dry biopharmaceutical formulations. In fact, around 30% of the FDA approved parenteral drugs are in lyophilized form. Since 2014, the FDA had approved more than 20 applications for lyophilized new drugs. Evidently, this method of producing stabilized formulations has witnessed widespread adoption and the affiliated market opportunity is estimated to be USD 3 billion. The increased adoption of such drugs has led to the rise in demand for reconstitution systems that allow proper mixing of lyophilized drug with the diluent and administration of required dose. The traditional reconstitution methods involve manual extraction and transfer of diluent into the vials containing the lyophilized product, using syringe and transfer needle. Given the large number of steps involved and multiple containers, this method is associated with the risk of medication errors and needle-stick injuries. In addition, the complexity associated with these conventional systems restricts the injection of lyophilized drugs only by the healthcare workers within the confined area of healthcare facilities.


The existing challenges in the conventional reconstitution method have prompted the pharmaceutical industry to develop advanced reconstitution devices, which allow the patients and caregivers to administer drugs without healthcare provider’s intervention. These systems contain premeasured dose of drug and diluent, which essentially reduces the chances of dosing errors and needle-stick injuries. Moreover, these advanced systems enhance the portability, efficiency and optimum delivery of the lyophilized drugs and have the potential to reduce the number of steps significantly, which enable the dilution and reconstitution at the time of delivery. Owing to their multiple benefits, various pharmaceutical companies are considering these systems for lifecycle management of their drugs in order to enhance the provision of healthcare. Further, it is worth mentioning that over 1,800 patent applications have been filed/granted for reconstitution systems and affiliated technologies. We believe that such efforts are likely to drive growth in this market over the coming years. 


Scope of the Report

The ‘Novel Drug Reconstitution Systems Market by Type of Container (Cartridge, Infusion Bag and Prefilled Syringe), Fabrication Material (Glass and Plastic), Physical State of Drug in Syringe and Cartridge (Liquid/Powder, Liquid/Liquid), Physical State of Drug in Infusion Bag (Liquid Mixture, Frozen Mixture), Volume of Container (<1 mL, 1-2.5 mL, 2.5-5 mL, >5 mL for prefilled syringe and cartridge; <250 mL, 250-500 mL, 500-1,000 mL, >1,000 mL for infusion bag), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030’ report features an extensive study on the current and future potential of novel drug reconstitution systems, being developed in order to ease the storage and administration of lyophilized drugs, thereby maintaining stability and shelf-life. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. 


Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of novel drug reconstitution systems, providing information on the type of device (prefilled syringe, cartridge, infusion bags), type of chamber (dual chamber, multi chamber), physical state of drug (lyophilized, liquid), container fabrication material (glass, plastic), device usability (single use, multi-use), and volume of container. In addition, the chapter includes details related to novel drug reconstitution system manufacturers, along with information on their year of establishment, company size, location of headquarters and key players (in terms of number of products manufactured).
  • A detailed landscape of the reconstitution devices and systems featuring information on type of container or device, volume of primary container, physical state of drug, device usability and provision for self-administration. In addition, the chapter includes details related to the manufacturers, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of prominent players engaged in this domain. Each profile includes a brief overview of the company, details related to its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • A detailed analysis on the trends in packaging of over 350 drug products (including both biologics and small molecule drugs) that were approved by the FDA between 2014 and H1 2021, featuring an assessment of the packaging requirements of various container-closure systems based on several parameters, such as year of approval of drug, type of molecule (small molecule, biologic), type of biologic (allogeneic cell therapy, autologous cell therapy, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant enzymes, recombinant protein and viral cell therapy), type of primary packaging container used (vials, pouches/packets, bottles, IV/sealed bags, prefilled syringes/pen , tubes, cartridge, blister packaging, others), type of packaging material(s) used for manufacturing primary container, type of closure used (cap/needle shield, seal, plunger, stopper and others), type of packaging material(s) used for manufacturing closures, dosage form, route of administration, holding temperature. In addition, the chapter provides information on the developers of the aforementioned drugs and an analysis based on year of establishment, company size, location of headquarters and leading drug developers (in terms of number of drugs approved).
  • An insightful analysis of the patents filed/granted for novel drug reconstitution systems, since 2011, taking into consideration various relevant parameters, such as type of patent, publication year, geographical location, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted/filed in the given time period), patent characteristics and geography. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • A competitiveness analysis of novel drug reconstitution system manufacturers based on various relevant parameters, such as supplier power (in terms of experience/expertise of the manufacturer) and key product specifications (number of systems, type of systems, type of drugs and number of chambers).
  • An in-depth analysis of recent events (summits/forums/conferences/annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to novel drug reconstitution systems. The analysis also provides details on type of event, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming events.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel drug reconstitution systems market.
  • An in-depth analysis to estimate the current and future demand for various novel drug reconstitution systems, including cartridges, infusion bags and prefilled syringes. 
  • An elaborate discussion on emerging trends that are likely to have an impact on the future adoption of novel drug reconstitution systems. It presents a Harvey ball analysis, highlighting the relative effect of each trend on the adoption of novel drug reconstitution systems including dual chamber systems.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for novel drug reconstitution systems, over the next decade. Based on various parameters, such as target consumer segments, likely adoption rates and expected prices of such products, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of reconstitution system (prefilled syringe/cartridge/infusion bag), [B] physical state of drug (liquid/powder, liquid/liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), [C] type of fabrication material (glass, plastic/type of plastic for infusion bags), [D] volume of container (<1 mL, 1-2.5 mL, 2.5-5 mL and >5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and >1,000 mL for infusion bags), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.


All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered

  • Who are the key players engaged in the development of novel drug reconstitution systems?
  • What is the relative competitiveness of different novel drug reconstitution system manufacturers?
  • What is the packaging trend in terms of container and closure for the drugs approved since 2014?
  • Who are the leading players focused on the development of lyophilized drugs?
  • What is the focus area of various conferences conducted in this domain?
  • How has the intellectual property landscape in this domain evolved over the years?
  • What are the emerging trends related to pharmaceutical packaging?
  • What are the key agenda items being discussed in various global events/conferences held in this domain?
  • How is the current and future market opportunity, likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Innovative Properties
  • Baxter
  • EMD Serono
  • JW Chemi Town
  • Pfizer
  • Strongbridge Biopharma

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Reconstitution Systems
3.2.1. Key Considerations in Drug Reconstitution
3.3. Lyophilization of Pharmaceuticals
3.3.1. Need for Reconstitution Systems
3.3.2. Dual Chamber/Multi Chamber Systems
3.3.3. One Step Reconstitution Systems
3.3.4. Conventional Reconstitution Systems
3.4. Advantages of Drug Reconstitution Systems
3.4.1. Benefits to Pharmaceutical Players
3.4.2. Benefits to Patients
3.5. Concluding Remarks


4. MARKET LANDSCAPE: NOVEL DRUG RECONSTITUTION SYSTEMS
4.1. Chapter Overview
4.2. Novel Drug Reconstitution Systems: Product Pipeline
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Type of Chamber
4.2.3. Analysis by Type of Device and Type of Chamber
4.2.4. Analysis by Physical State of Drug
4.2.5. Analysis by Container Fabrication Material
4.2.6. Analysis by Device Usability
4.2.7. Analysis by Container Fabrication Material and Device Usability
4.2.8. Analysis by Volume of Container
4.3. Novel Drug Reconstitution Systems: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Region of Headquarters
4.3.4. Analysis by Company Size and Region of Headquarters
4.3.5. Analysis by Location of Headquarters
4.3.6. Leading Players: Analysis by Number of Novel Drug Reconstitution Systems Manufactured


5. MARKET LANDSCAPE: OTHER RECONSTITUTION SYSTEMS
5.1. Chapter Overview
5.2. One Step Reconstitution Systems: Product Pipeline
5.2.1. Analysis by Type of Primary Container
5.2.2. Analysis by Volume of Primary Container
5.2.3. Analysis by Physical State of Drug
5.2.4. Analysis by Device Usability
5.2.5. Analysis by Type of Primary Container and Physical State of Drug
5.3. One Step Reconstitution Systems: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Leading Players: Analysis by Number of One Step Reconstitution Systems Manufactured
5.4. Conventional Reconstitution Devices: Development Pipeline
5.4.1. Analysis by Status of Development
5.4.2. Analysis by Type of Device
5.4.3. Analysis by Type of Primary Container
5.4.4. Analysis by Physical State of Drug
5.4.5. Analysis by Type of Primary Container and Physical State of Drug
5.5. Conventional Reconstitution Devices: Developer Landscape
5.5.1. Analysis by Year of Establishment
5.5.2. Analysis by Company Size
5.5.3. Analysis by Location of Headquarters
5.5.4. Analysis by Region of Headquarters
5.5.5. Leading Players: Analysis by Number of Conventional Reconstitution Devices Manufactured


6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Baxter
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. ICU Medical
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. B. Braun
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Product Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Vetter Pharma
6.3.2.1. Company Overview
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. Nipro
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Product Portfolio
6.4.1.4. Recent Developments and Future Outlook
6.4.2. SCHOTT-KAISHA
6.4.2.1. Company Overview
6.4.2.2. Product Portfolio
6.4.2.3. Recent Developments and Future Outlook


7. PACKAGING TREND ANALYSIS FOR APPROVED DRUGS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. List of Approved Drugs (2014-H1 2021)
7.3.1. Analysis by Type of Molecule and Approval Year
7.3.2. Analysis by Type of Molecule
7.3.3. Analysis by Type of Biologic
7.3.4. Analysis by Type of Molecule and Holding Temperature
7.3.5. Analysis by Type of Biologic and Dosage Form
7.4. Primary Packaging Containers for Approved Drugs
7.4.1. Analysis by Type of Primary Packaging Container
7.4.2. Analysis by Type of Primary Packaging Container and Approval Year
7.4.3. Analysis by Type of Primary Packaging Container and Type of Molecule
7.4.4. Analysis by Type of Primary Packaging Container and Holding Temperature Range
7.4.5. Analysis by Type of Primary Packaging Container and Dosage Form
7.4.6. Analysis by Type of Primary Packaging Container and Route of Administration
7.4.7. Most Popular Materials Used for Containers: Analysis by Number of Drugs
7.5. Primary Packaging Closures for Approved Drugs
7.5.1. Analysis by Type of Primary Packaging Closure
7.5.2. Analysis by Type of Primary Packaging Closure and Approval Year
7.5.3. Analysis by Type of Primary Packaging Closure and Type of Molecule
7.5.4. Analysis by Type of Primary Packaging Closure and Holding Temperature Range
7.5.5. Analysis by Type of Primary Packaging Closure and Dosage Form
7.5.6. Analysis by Type of Primary Packaging Closure and Route of Administration
7.5.7. Most Popular Materials Used for Closures: Analysis by Number of Drugs
7.6. Packaging Trend Analysis for Approved Drugs: Developer Landscape
7.6.1. Analysis by Year of Establishment
7.6.2. Analysis by Company Size
7.6.3. Analysis by Location of Headquarters
7.6.4. Analysis by Type of Molecules and Company Size
7.6.5. Analysis by Type of Molecule and Geographical Location of Developers
7.6.6. Analysis by Type of Biologics and Geographical Location of Developers
7.6.7. Most Active Players: Analysis by Type of Molecule
7.6.8. Most Active Players: Analysis by Number of Biologics Developed
7.6.9. Most Active Players: Analysis by Type of Biologic
7.6.10. Most Active Players: Analysis by Number of Small Molecules Developed
7.7. Concluding Remarks


8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Drug Reconstitution Systems: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Application Year
8.3.3. Analysis by Geographical Location
8.3.4. Analysis by CPC Symbols
8.3.5. Word Cloud: Emerging Focus Areas
8.3.6. Analysis by Type of Organization
8.3.7. Leading Players: Analysis by Number of Patents
8.4. Novel Drug Reconstitution Systems: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Novel Drug Reconstitution Systems: Patent Valuation Analysis
8.6. Leading Patents by Number of Citations


9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions/Key Parameters
9.3. Methodology
9.4. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
9.5. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
9.6. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World


10. GLOBAL EVENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Global Events related to Novel Drug Reconstitution Systems
10.3.1. Analysis by Year of Event
10.3.2. Analysis by Event Platform
10.3.3. Analysis by Type of Event
10.3.4. Analysis by Geography
10.3.5. Word Cloud: Evolutionary Trends in Event Agenda/Key Focus Area
10.3.6. Most Active Event Organizers
10.3.7. Most Active Participants: Analysis by Number of Events
10.3.8. Analysis by Seniority Level of Participants
10.3.9. Most Active Speakers: Analysis by Number of Events
10.3.10. Geographical Mapping of Upcoming Events


11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Novel Drug Reconstitution Systems: SWOT Analysis
11.2.1. Comparison of SWOT Factors


12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Global Demand for Dual Chamber Prefilled Syringes, 2021-2030
12.3.1. Analysis by Physical State of Drug
12.3.1.1. Global Demand of Dual Chamber Prefilled Syringes for Liquid/Powder Drugs, 2021-2030
12.3.1.2. Global Demand of Dual Chamber Prefilled Syringes for Liquid/Liquid Drugs, 2021-2030
12.3.2. Analysis by Type of Fabrication Material
12.3.2.1. Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030
12.3.2.2. Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030
12.3.3. Analysis by Volume
12.3.3.1. Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030
12.3.3.2. Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030
12.3.3.3. Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030
12.3.3.4. Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030
12.3.4. Analysis by Geography
12.3.4.1. Global Demand of Dual Chamber Prefilled Syringes in North America, 2021-2030
12.3.4.2. Global Demand of Dual Chamber Prefilled Syringes in Europe, 2021-2030
12.3.4.3. Global Demand of Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030
12.3.4.4. Global Demand of Dual Chamber Prefilled Syringes in Latin America, 2021-2030
12.3.4.5. Global Demand of Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030
12.4. Global Demand for Dual Chamber Cartridges, 2021-2030
12.4.1. Analysis by Physical State of Drug
12.4.1.1. Global Demand of Dual Chamber Cartridges for Liquid/Powder Drugs, 2021-2030
12.4.1.2. Global Demand of Dual Chamber Cartridges for Liquid/Liquid Drugs, 2021-2030
12.4.2. Analysis by Type of Fabrication Material
12.4.2.1. Global Demand for Glass Dual Chamber Cartridges, 2021-2030
12.4.2.2. Global Demand for Plastic Dual Chamber Cartridges, 2021-2030
12.4.3. Analysis by Volume
12.4.3.1. Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030
12.4.3.2. Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030
12.4.3.3. Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030
12.4.3.4. Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030
12.4.4. Analysis by Geography
12.4.4.1. Global Demand of Dual Chamber Cartridges in North America, 2021-2030
12.4.4.2. Global Demand of Dual Chamber Cartridges in Europe, 2021-2030
12.4.4.3. Global Demand of Dual Chamber Cartridges in Asia-Pacific, 2021-2030
12.4.4.4. Global Demand of Dual Chamber Cartridges in Latin America, 2021-2030
12.4.4.5. Global Demand of Dual Chamber Cartridges in Middle East and Africa, 2021-2030
12.4.4.6. Global Demand of Dual Chamber Cartridges in Rest of the World, 2021-2030
12.5. Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.1. Analysis by Physical State of Drug
12.5.1.1. Global Demand of Dual/Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030
12.5.1.2. Global Demand of Dual/Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030
12.5.2. Analysis by Type of Plastic
12.5.2.1. Global Demand of Ethylene Vinyl Acetate made Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.2.2. Global Demand of Polypropylene made Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.2.3. Global Demand of Polyvinyl Chloride made Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.2.4. Global Demand of Other Plastic made Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.3. Analysis by Volume
12.5.3.1. Global Demand for 0-250 mL Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.3.2. Global Demand for 250-500 mL Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.3.3. Global Demand for 500-1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.3.4. Global Demand for >1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030
12.5.4. Analysis by Geography
12.5.4.1. Global Demand of Dual/Multi Chamber Infusion Bags in North America, 2021-2030
12.5.4.2. Global Demand of Dual/Multi Chamber Infusion Bags in Europe, 2021-2030
12.5.4.3. Global Demand of Dual/Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030
12.5.4.4. Global Demand of Dual/Multi Chamber Infusion Bags in Latin America, 2021-2030
12.5.4.5. Global Demand of Dual/Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030
12.6. Concluding Remarks


13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Methodology and Key Assumptions
13.3. Global Dual Chamber Prefilled Syringes Market, 2021-2030
13.3.1. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
13.3.1.1. Dual Chamber Prefilled Syringes Market for Liquid/Powder Drugs, 2021-2030
13.3.1.2. Dual Chamber Prefilled Syringes Market for Liquid/Liquid Drugs, 2021-2030
13.3.2. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
13.3.2.1. Glass Dual Chamber Prefilled Syringes Market, 2021-2030
13.3.2.2. Plastic Dual Chamber Prefilled Syringes Market, 2021-2030
13.3.3. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
13.3.3.1. Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030
13.3.3.2. Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030
13.3.3.3. Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030
13.3.3.4. Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030
13.3.4. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
13.3.4.1. Dual Chamber Prefilled Syringes Market in North America, 2021-2030
13.3.4.2. Dual Chamber Prefilled Syringes Market in Europe, 2021-2030
13.3.4.3. Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030
13.3.4.4. Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030
13.3.4.5. Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030
13.4. Global Dual Chamber Cartridges Market, 2021-2030
13.4.1. Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
13.4.1.1. Dual Chamber Cartridges Market for Liquid/Powder Drugs, 2021-2030
13.4.1.2. Dual Chamber Cartridges Market for Liquid/Liquid Drugs, 2021-2030
13.4.2. Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
13.4.2.1. Glass Dual Chamber Cartridges Market, 2021-2030
13.4.2.2. Plastic Dual Chamber Cartridges Market, 2021-2030
13.4.3. Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
13.4.3.1. Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030
13.4.3.2. Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030
13.4.3.3. Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030
13.4.3.4. Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030
13.4.4. Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
13.4.4.1. Dual Chamber Cartridges Market in North America, 2021-2030
13.4.4.2. Dual Chamber Cartridges Market in Europe, 2021-2030
13.4.4.3. Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030
13.4.4.4. Dual Chamber Cartridges Market in Latin America, 2021-2030
13.4.4.5. Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030
13.4.4.6. Dual Chamber Cartridges Market in Rest of the World, 2021-2030
13.5. Global Dual/Multi Chamber Infusion Bags Market, 2021-2030
13.5.1. Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
13.5.1.1. Dual/Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030
13.5.1.2. Dual/Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030
13.5.2. Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
13.5.2.1. Dual/Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030
13.5.2.2. Dual/Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030
13.5.2.3. Dual/Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030
13.5.2.4. Dual/Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030
13.5.3. Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
13.5.3.1. Dual/Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030
13.5.3.2. Dual/Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030
13.5.3.3. Dual/Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030
13.5.3.4. Dual/Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030
13.5.4. Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
13.5.4.1. Dual/Multi Chamber Infusion Bags Market in North America, 2021-2030
13.5.4.2. Dual/Multi Chamber Infusion Bags Market in Europe, 2021-2030
13.5.4.3. Dual/Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030
13.5.4.4. Dual/Multi Chamber Infusion Bags Market in Latin America, 2021-2030
13.5.4.5. Dual/Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030


14. UPCOMING TRENDS IN PHARMACEUTICAL PACKAGING
14.1. Chapter Overview
14.2. Preference for Self-Medication of Drugs using Modern Drug Delivery Devices
14.3. Development of Innovative Packaging Containers
14.4. Growing Demand for Personalized Therapies
14.5. Integrating Dual Chamber Systems with Other Platforms
14.6. Increase in Initiatives Undertaken by Industry Stakeholders in Developing Regions
14.7. Concluding Remarks


15. CONCLUDING REMARKS16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Overall Market Landscape
Figure 2.3 Executive Summary: Packaging Trend Analysis for Approved Drugs
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Global Event Analysis
Figure 2.6 Executive Summary: Demand Analysis
Figure 3.1 Basic Steps of Reconstitution
Figure 3.2 Factors Affecting Reconstitution of Drugs
Figure 3.3 Steps Involved in Lyophilization of Pharmaceuticals
Figure 3.4 Benefits of Reconstitution to Pharmaceutical Players
Figure 3.5 Benefits of Reconstitution to Patients
Figure 4.1 Novel Drug Reconstitution Systems: Distribution by Type of Device
Figure 4.2 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Figure 4.3 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
Figure 4.4 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Figure 4.5 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Figure 4.6 Novel Drug Reconstitution Systems: Distribution by Device Usability
Figure 4.7 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
Figure 4.8 Novel Drug Reconstitution Systems: Distribution by Volume of Container
Figure 4.9 Novel Drug Reconstitution System Developers: Distribution by Year of Establishment
Figure 4.10 Novel Drug Reconstitution System Developers: Distribution by Company Size
Figure 4.11 Novel Drug Reconstitution System Developers: Distribution by Region of Headquarters
Figure 4.12 Novel Drug Reconstitution System Developers: Distribution by Company Size and Region of Headquarters
Figure 4.13 Novel Drug Reconstitution System Developers: Distribution by Location of Headquarters
Figure 4.14 Leading Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
Figure 5.1 One Step Reconstitution Systems: Distribution by Type of Primary Container
Figure 5.2 One Step Reconstitution Systems: Distribution by Volume of Primary Container
Figure 5.3 One Step Reconstitution Systems: Distribution by Physical State of Drug
Figure 5.4 One Step Reconstitution Systems: Distribution by Device Usability
Figure 5.5 One Step Reconstitution Systems: Distribution by Type of Primary Container and Physical State of Drug
Figure 5.6 One Step Reconstitution System Developers: Distribution by Year of Establishment
Figure 5.7 One Step Reconstitution System Developers: Distribution by Company Size
Figure 5.8 One Step Reconstitution System Developers: Distribution by Location of Headquarters
Figure 5.9 Leading Players: Distribution by Number of One Step Reconstitution Systems Manufactured
Figure 5.10 Conventional Reconstitution Devices: Distribution by Status of Development
Figure 5.11 Conventional Reconstitution Devices: Distribution by Type of Device
Figure 5.12 Conventional Reconstitution Devices: Distribution by Type of Primary Container
Figure 5.13 Conventional Reconstitution Devices: Distribution by Physical State of Drug
Figure 5.14 Conventional Reconstitution Devices: Distribution by Type of Primary Container and Physical State of Drug
Figure 5.15 Conventional Reconstitution Device Developers: Distribution by Year of Establishment
Figure 5.16 Conventional Reconstitution Device Developers: Distribution by Company Size
Figure 5.17 Conventional Reconstitution Device Developers: Distribution by Location of Headquarters
Figure 5.18 Conventional Reconstitution Device Developers: Distribution of Manufacturers by Region of Headquarters
Figure 5.19 Leading Players: Distribution by Number of Conventional Reconstitution Devices Manufactured
Figure 6.1 Baxter: Annual Revenues, 2016-Q1 2021 (USD Billion)
Figure 6.2 ICU Medical: Annual Revenues, 2016-Q1 2021 (USD Billion)
Figure 6.3 B. Braun: Annual Revenues, 2016-FY 2020 (EUR Billion)
Figure 6.4 Nipro: Annual Revenues, 2016-FY 2021 (JPY Billion)
Figure 7.1 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Approval Year
Figure 7.2 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule
Figure 7.3 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic
Figure 7.4 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Holding Temperature
Figure 7.5 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic and Dosage Form
Figure 7.6 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container
Figure 7.7 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Approval Year
Figure 7.8 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Type of Molecule
Figure 7.9 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Holding Temperature Range
Figure 7.10 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Dosage Form
Figure 7.11 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Route of Administration
Figure 7.12 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Biologics
Figure 7.13 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Small Molecules
Figure 7.14 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure
Figure 7.15 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Approval Year
Figure 7.16 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Type of Molecule
Figure 7.17 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Holding Temperature Range
Figure 7.18 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Dosage Form
Figure 7.19 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Route of Administration
Figure 7.20 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Biologics
Figure 7.21 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Small Molecules
Figure 7.22 Approved Drug Developers: Distribution by Year of Establishment
Figure 7.23 Approved Drug Developers: Distribution by Company Size
Figure 7.24 Approved Drug Developers: Distribution by Location of Headquarters
Figure 7.25 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Company Size
Figure 7.26 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Geographical Location of Developers
Figure 7.27 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in North America
Figure 7.28 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Europe
Figure 7.29 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Asia-Pacific
Figure 7.30 Most Active Players: Distribution by Type of Molecule
Figure 7.31 Most Active Players: Distribution by Number of Biologics Developed
Figure 7.32 Most Active Players: Distribution by Type of Biologic
Figure 7.33 Most Active Players: Distribution by Number of Small Molecule Drugs Developed
Figure 7.34 Approved Drugs (2014-H1 2021), Grid Analysis: Distribution by Type of Container, Closure, Type of Material and Route of Administration
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021
Figure 8.3 Patent Analysis: Cumulative Distribution by Application Year, 2011-2021
Figure 8.4 Patent Analysis: Distribution by Geographical Location
Figure 8.5 Patent Analysis: Distribution by CPC Symbols
Figure 8.6 Word Cloud: Emerging Focus Areas
Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2011-2021
Figure 8.8 Leading Players: Distribution by Number of Patents
Figure 8.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 8.10 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.11 Patent Analysis: Year-wise Distribution of Patents by Age, 2001-2020
Figure 8.12 Novel Drug Reconstitution Systems: Patent Valuation Analysis
Figure 9.1 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
Figure 9.2 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
Figure 9.3 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World
Figure 10.1 Global Events: Cumulative Half Yearly Trend, H2 2015-H1 2022
Figure 10.2 Global Events: Distribution by Event Platform
Figure 10.3 Global Events: Distribution by Type of Event
Figure 10.4 Global Events: Distribution by Location of Event
Figure 10.5 Word Cloud: Evolutionary Trends in Event Agenda/Key Focus Area
Figure 10.6 Global Events: Historical Trend of Event Agendas, 2015-H1 2022
Figure 10.7 Global Events: Distribution by Event Organizers
Figure 10.8 Most Active Industry Participants: Distribution by Number of Events
Figure 10.9 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 10.10 Global Events: Distribution by Designation of Participant
Figure 10.11 Global Events: Distribution by Affiliated Department of Participant
Figure 10.12 Most Active Speakers: Distribution by Number of Events
Figure 10.13 Global Events: Geographical Mapping of Upcoming Events
Figure 11.1 Novel Drug Reconstitution Systems: SWOT Analysis
Figure 11.2 SWOT Factors: Harvey Ball Analysis
Figure 12.1 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.2 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Physical State of Drug
Figure 12.3 Global Demand for Dual Chamber Prefilled Syringes for Liquid/Powder Drugs, 2021-2030 (Billion Units)
Figure 12.4 Global Demand for Dual Chamber Prefilled Syringes for Liquid/Liquid Drugs, 2021-2030 (Billion Units)
Figure 12.5 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Type of Fabrication Material
Figure 12.6 Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.7 Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.8 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Volume
Figure 12.9 Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.10 Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.11 Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.12 Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Figure 12.13 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Geography
Figure 12.14 Global Demand for Dual Chamber Prefilled Syringes in North America, 2021-2030 (Billion Units)
Figure 12.15 Global Demand for Dual Chamber Prefilled Syringes in Europe, 2021-2030 (Billion Units)
Figure 12.16 Global Demand for Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030 (Billion Units)
Figure 12.17 Global Demand for Dual Chamber Prefilled Syringes in Latin America, 2021-2030 (Billion Units)
Figure 12.18 Global Demand for Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030 (Billion Units)
Figure 12.19 Global Demand for Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.20 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Physical State of Drug
Figure 12.21 Global Demand for Dual Chamber Cartridges for Liquid/Powder Drugs, 2021-2030 (Billion Units)
Figure 12.22 Global Demand for Dual Chamber Cartridges for Liquid/Liquid Drugs, 2021-2030 (Billion Units)
Figure 12.23 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Type of Fabrication Material
Figure 12.24 Global Demand for Glass Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.25 Global Demand for Plastic Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.26 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Volume
Figure 12.27 Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.28 Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.29 Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.30 Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Figure 12.31 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Geography
Figure 12.32 Global Demand for Dual Chamber Cartridges in North America, 2021-2030 (Billion Units)
Figure 12.33 Global Demand for Dual Chamber Cartridges in Europe, 2021-2030 (Billion Units)
Figure 12.34 Global Demand for Dual Chamber Cartridges in Asia-Pacific, 2021-2030 (Billion Units)
Figure 12.35 Global Demand for Dual Chamber Cartridges in Latin America, 2021-2030 (Billion Units)
Figure 12.36 Global Demand for Dual Chamber Cartridges in Middle East and Africa, 2021-2030 (Billion Units)
Figure 12.37 Global Demand for Dual Chamber Cartridges in Rest of the World, 2021-2030 (Billion Units)
Figure 12.38 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.39 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Physical State of Drug
Figure 12.40 Global Demand for Dual/Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030 (Billion Units)
Figure 12.41 Global Demand for Dual/Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030 (Billion Units)
Figure 12.42 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Type of Plastic
Figure 12.43 Global Demand for Ethylene Vinyl Acetate Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.44 Global Demand for Polypropylene Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.45 Global Demand for Polyvinyl Chloride Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.46 Global Demand for Other Plastic Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.47 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Volume
Figure 12.48 Global Demand for 0-250 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.49 Global Demand for 250-500 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.50 Global Demand for 500-1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.51 Global Demand for >1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Figure 12.52 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Geography
Figure 12.53 Global Demand for Dual/Multi Chamber Infusion Bags in North America, 2021-2030 (Billion Units)
Figure 12.54 Global Demand for Dual/Multi Chamber Infusion Bags in Europe, 2021-2030 (Billion Units)
Figure 12.55 Global Demand for Dual/Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030 (Billion Units)
Figure 12.56 Global Demand for Dual/Multi Chamber Infusion Bags in Latin America, 2021-2030 (Billion Units)
Figure 12.57 Global Demand for Dual/Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030 (Billion Units)
Figure 13.1 Global Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 13.2 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
Figure 13.3 Dual Chamber Prefilled Syringes Market for Liquid/Powder Drugs, 2021-2030 (USD Billion)
Figure 13.4 Dual Chamber Prefilled Syringes Market for Liquid/Liquid Drugs, 2021-2030 (USD Billion)
Figure 13.5 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
Figure 13.6 Glass Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 13.7 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 13.8 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
Figure 13.9 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030 (USD Billion)
Figure 13.10 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030 (USD Billion)
Figure 13.11 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030 (USD Billion)
Figure 13.12 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030 (USD Billion)
Figure 13.13 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
Figure 13.14 Dual Chamber Prefilled Syringes Market in North America, 2021-2030 (USD Billion)
Figure 13.15 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030 (USD Billion)
Figure 13.16 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.17 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030 (USD Billion)
Figure 13.18 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 13.19 Global Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 13.20 Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
Figure 13.21 Dual Chamber Cartridges Market for Liquid/Powder Drugs, 2021-2030 (USD Billion)
Figure 13.22 Dual Chamber Cartridges Market for Liquid/Liquid Drugs, 2021-2030 (USD Billion)
Figure 13.23 Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
Figure 13.24 Glass Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 13.25 Plastic Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 13.26 Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
Figure 13.27 Dual Chamber Cartridges Market for 1 mL Cartridges, 2021-2030 (USD Billion)
Figure 13.28 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030 (USD Billion)
Figure 13.29 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030 (USD Billion)
Figure 13.30 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030 (USD Billion)
Figure 13.31 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
Figure 13.32 Dual Chamber Cartridges Market in North America, 2021-2030 (USD Billion)
Figure 13.33 Dual Chamber Cartridges Market in Europe, 2021-2030 (USD Billion)
Figure 13.34 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.35 Dual Chamber Cartridges Market in Latin America, 2021-2030 (USD Billion)
Figure 13.36 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 13.37 Dual Chamber Cartridges Market in Rest of the World, 2021-2030 (USD Billion)
Figure 13.38 Global Dual/Multi Chamber Infusion Bags Market, 2021-2030 (USD Billion)
Figure 13.39 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
Figure 13.40 Dual/Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030 (USD Billion)
Figure 13.41 Dual/Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030 (USD Billion)
Figure 13.42 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
Figure 13.43 Dual/Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030 (USD Billion)
Figure 13.44 Dual/Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030 (USD Billion)
Figure 13.45 Dual/Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030 (USD Billion)
Figure 13.46 Dual/Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030 (USD Billion)
Figure 13.47 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
Figure 13.48 Dual/Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030 (USD Billion)
Figure 13.49 Dual/Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030 (USD Billion)
Figure 13.50 Dual/Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030 (USD Billion)
Figure 13.51 Dual/Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030 (USD Billion)
Figure 13.52 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
Figure 13.53 Dual/Multi Chamber Infusion Bags Market in North America, 2021-2030 (USD Billion)
Figure 13.54 Dual/Multi Chamber Infusion Bags Market in Europe, 2021-2030 (USD Billion)
Figure 13.55 Dual/Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.56 Dual/Multi Chamber Infusion Bags Market in Latin America, 2021-2030 (USD Billion)
Figure 13.57 Dual/Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 14.1 Upcoming Trends Related to Pharmaceutical Packaging
Figure 14.2 Future Growth Opportunities of Dual Chamber Packaging Systems Based on Recent Trends
Figure 15.1 Concluding Remarks: Novel Drug Reconstitution Systems Market Landscape
Figure 15.2 Concluding Remarks: Other Reconstitution Systems Market Landscape
Figure 15.3 Concluding Remarks:Packaging Trend Analysis for Approved Drugs
Figure 15.4 Concluding Remarks: Patent Analysis
Figure 15.5 Concluding Remarks: Company Competitiveness Analysis
Figure 15.6 Concluding Remarks: Global Event Analysis
Figure 15.7 Concluding Remarks:Demand Analysis
Figure 15.8 Concluding Remarks: Market Forecast and Opportunity Analysis


List Of Tables
Table 4.1 Novel Drug Reconstitution Systems: Information on Type of Product, Number of Chambers, Physical State of Drug and Product Certifications
Table 4.2 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Volume, Drug Class, Device Usability and Provisions for Self-Administration
Table 4.3 Novel Drug Reconstitution Systems: Developer Landscape
Table 5.1 One Step Reconstitution Systems: Information on Status of Development, Type of Primary Container, Volume and Product Certifications
Table 5.2 One Step Reconstitution Systems: Information on Physical State of Drug, Device Usability, Provisions for Self-Administration and Route of Administration
Table 5.3 One Step Reconstitution Systems: Developer Landscape
Table 5.4 Conventional Reconstitution Devices: Information on Status of Development, Type of Device, Type of Primary Container, Volume and Product Certifications
Table 5.5 Conventional Reconstitution Devices: Information on Physical State of Drug, Device Usability, Provisions for Self-Administration and Route of Administration
Table 5.6 Conventional Reconstitution Devices: Developer Landscape
Table 6.1 Novel Drug Reconstitution System Manufacturers: List of Companies Profiled
Table 6.2  Baxter: Company Snapshot
Table 6.3 Baxter: Product Portfolio
Table 6.4 Baxter: Recent Developments and Future Outlook
Table 6.5 ICU Medical: Company Snapshot
Table 6.6 ICU Medical: Product Portfolio
Table 6.7 ICU Medical: Recent Developments and Future Outlook
Table 6.8 B. Braun: Company Snapshot
Table 6.9 B. Braun: Product Portfolio
Table 6.10 B. Braun: Recent Developments and Future Outlook
Table 6.11 Vetter Pharma: Company Snapshot
Table 6.12 Vetter Pharma: Product Portfolio
Table 6.13 Vetter Pharma: Recent Developments and Future Outlook
Table 6.14 Nipro: Company Snapshot
Table 6.15 Nipro: Product Portfolio
Table 6.16 Nipro: Recent Developments and Future Outlook
Table 6.17 SCHOTT-KAISHA: Company Snapshot
Table 6.18 SCHOTT-KAISHA: Product Portfolio
Table 6.19 SCHOTT-KAISHA: Recent Developments and Future Outlook
Table 7.1 List of Approved Drugs (2014-H1 2021): Information on Dosage Form, Route of Administration and Holding Temperature Range
Table 7.2 List of Approved Drugs (2014-H1 2021): Information on Type of Container and Container Material
Table 7.3 List of Approved Drugs (2014-H1 2021): Information on Type of Closure and Closure Material
Table 8.1 Patent Analysis: CPC Symbol Definitions
Table 8.2 Patent Analysis: Popular CPC Symbols
Table 8.3 Patent Analysis: CPC Classification Symbol Definitions
Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 8.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 10.1 List of Global Events related to Novel Drug Reconstitution Systems
Table 16.1 Novel Drug Reconstitution Systems: Distribution by Type of Device
Table 16.2 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Table 16.3 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
Table 16.4 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Table 16.5 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Table 16.6 Novel Drug Reconstitution Systems: Distribution by Device Usability
Table 16.7 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
Table 16.8 Novel Drug Reconstitution Systems: Distribution by Volume of Container
Table 16.9 Novel Drug Reconstitution System Developers: Distribution by Year of Establishment
Table 16.10 Novel Drug Reconstitution System Developers: Distribution by Company Size
Table 16.11 Novel Drug Reconstitution System Developers: Distribution by Region of Headquarters
Table 16.12 Novel Drug Reconstitution System Developers: Distribution by Company Size and Region of Headquarters
Table 16.13 Novel Drug Reconstitution System Developers: Distribution by Location of Headquarters
Table 16.14 Leading Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
Table 16.15 One Step Reconstitution Systems: Distribution by Type of Primary Container
Table 16.16 One Step Reconstitution Systems: Distribution by Volume of Primary Container
Table 16.17 One Step Reconstitution Systems: Distribution by Physical State of Drug
Table 16.18 One Step Reconstitution Systems: Distribution by Device Usability
Table 16.19 One Step Reconstitution Systems: Distribution by Type of Primary Container and Physical State of Drug
Table 16.20 One Step Reconstitution System Developers: Distribution by Year of Establishment
Table 16.21 One Step Reconstitution System Developers: Distribution by Company Size
Table 16.22 One Step Reconstitution System Developers: Distribution by Location of Headquarters
Table 16.23 Leading Players: Distribution by Number of One Step Reconstitution Systems Manufactured
Table 16.24 Conventional Reconstitution Devices: Distribution by Status of Development
Table 16.25 Conventional Reconstitution Devices: Distribution by Type of Device
Table 16.26 Conventional Reconstitution Devices: Distribution by Type of Primary Container
Table 16.27 Conventional Reconstitution Devices: Distribution by Physical State of Drug
Table 16.28 Conventional Reconstitution Devices: Distribution by Type of Primary Container and Physical State of Drug
Table 16.29 Conventional Reconstitution Device Developers: Distribution by Year of Establishment
Table 16.30 Conventional Reconstitution Device Developers: Distribution by Company Size
Table 16.31 Conventional Reconstitution Device Developers: Distribution by Location of Headquarters
Table 16.32 Conventional Reconstitution Device Developers: Distribution by Region of Headquarters
Table 16.33 Leading Players: Distribution by Number of Conventional Reconstitution Devices Manufactured
Table 16.34 Baxter: Annual Revenues, 2016-Q1 2021 (USD Billion)
Table 16.35 ICU Medical: Annual Revenues, 2016-Q1 2021 (USD Billion)
Table 16.36 B. Braun: Annual Revenues, 2016-FY 2020 (EUR Billion)
Table 16.37 Nipro: Annual Revenues, 2016-FY 2021 (JPY Billion)
Table 16.38 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Approval Year
Table 16.39 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule
Table 16.40 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic
Table 16.41 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Holding Temperature
Table 16.42 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic and Dosage Form
Table 16.43 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container
Table 16.44 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Approval Year
Table 16.45 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Type of Molecule
Table 16.46 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Holding Temperature Range
Table 16.47 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Dosage Form
Table 16.48 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Route of Administration
Table 16.49 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Biologics
Table 16.50 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Small Molecules
Table 16.51 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure
Table 16.52 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Approval Year
Table 16.53 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Type of Molecule
Table 16.54 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Holding Temperature Range
Table 16.55 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Dosage Form
Table 16.56 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Route of Administration
Table 16.57 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Biologics
Table 16.58 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Small Molecules
Table 16.59 Approved Drug Developers: Distribution by Year of Establishment
Table 16.60 Approved Drug Developers: Distribution by Company Size
Table 16.61 Approved Drug Developers: Distribution by Location of Headquarters
Table 16.62 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Company Size
Table 16.63 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Geographical Location of Developers
Table 16.64 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in North America
Table 16.65 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Europe
Table 16.66 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Asia-Pacific
Table 16.67 Most Active Players: Distribution by Type of Molecule
Table 16.68 Most Active Players: Distribution by Number of Biologics Developed
Table 16.69 Most Active Players: Distribution by Type of Biologic
Table 16.70 Most Active Players: Distribution by Number of Small Molecule Drugs Developed
Table 16.71 Approved Drugs (2014-H1 2021), Grid Analysis: Distribution by Type of Container, Closure, Type of Material and Route of Administration
Table 16.72 Patent Analysis: Distribution by Type of Patent
Table 16.73 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021
Table 16.74 Patent Analysis: Cumulative Distribution by Application Year, 2011-2021
Table 16.75 Patent Analysis: Distribution by Geographical Location
Table 16.76 Patent Analysis: Distribution by CPC Symbols
Table 16.77 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2011-2021
Table 16.78 Leading Players: Distribution by Number of Patents
Table 16.79 Leading Individual Assignees: Distribution by Number of Patents
Table 16.80 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Table 16.81 Patent Analysis: Year-wise Distribution of Patents by Age, 2001-2020
Table 16.82 Novel Drug Reconstitution Systems: Patent Valuation Analysis
Table 16.83 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
Table 16.84 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
Table 16.85 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World
Table 16.86 Global Events: Cumulative Half Yearly Trend, H2 2015-H1 2022
Table 16.87 Global Events: Distribution by Event Platform
Table 16.88 Global Events: Distribution by Type of Event
Table 16.89 Global Events: Distribution by Location of Event
Table 16.90 Global Events: Distribution by Event Organizers
Table 16.91 Most Active Industry Participants: Distribution by Number of Events
Table 16.92 Most Active Non-Industry Participants: Distribution by Number of Events
Table 16.93 Global Events: Distribution by Designation of Participant
Table 16.94 Global Events: Distribution by Affiliated Department of Participant
Table 16.95 Most Active Speakers: Distribution by Number of Events
Table 16.96 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.97 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Physical State of Drug
Table 16.98 Global Demand for Dual Chamber Prefilled Syringes for Liquid/Powder Drugs, 2021-2030 (Billion Units)
Table 16.99 Global Demand for Dual Chamber Prefilled Syringes for Liquid/Liquid Drugs, 2021-2030 (Billion Units)
Table 16.100 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Type of Fabrication Material
Table 16.101 Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.102 Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.103 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Volume
Table 16.104 Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.105 Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.106 Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.107 Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
Table 16.108 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Geography
Table 16.109 Global Demand for Dual Chamber Prefilled Syringes in North America, 2021-2030 (Billion Units)
Table 16.110 Global Demand for Dual Chamber Prefilled Syringes in Europe, 2021-2030 (Billion Units)
Table 16.111 Global Demand for Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030 (Billion Units)
Table 16.112 Global Demand for Dual Chamber Prefilled Syringes in Latin America, 2021-2030 (Billion Units)
Table 16.113 Global Demand for Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030 (Billion Units)
Table 16.114 Global Demand for Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.115 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Physical State of Drug
Table 16.116 Global Demand for Dual Chamber Cartridges for Liquid/Powder Drugs, 2021-2030 (Billion Units)
Table 16.117 Global Demand for Dual Chamber Cartridges for Liquid/Liquid Drugs, 2021-2030 (Billion Units)
Table 16.118 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Type of Fabrication Material
Table 16.119 Global Demand for Glass Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.120 Global Demand for Plastic Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.121 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Volume
Table 16.122 Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.123 Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.124 Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.125 Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
Table 16.126 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Geography
Table 16.127 Global Demand for Dual Chamber Cartridges in North America, 2021-2030 (Billion Units)
Table 16.128 Global Demand for Dual Chamber Cartridges in Europe, 2021-2030 (Billion Units)
Table 16.129 Global Demand for Dual Chamber Cartridges in Asia-Pacific, 2021-2030 (Billion Units)
Table 16.130 Global Demand for Dual Chamber Cartridges in Latin America, 2021-2030 (Billion Units)
Table 16.131 Global Demand for Dual Chamber Cartridges in Middle East and Africa, 2021-2030 (Billion Units)
Table 16.132 Global Demand for Dual Chamber Cartridges in Rest of the World, 2021-2030 (Billion Units)
Table 16.133 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.134 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Physical State of Drug
Table 16.135 Global Demand for Dual/Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030 (Billion Units)
Table 16.136 Global Demand for Dual/Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030 (Billion Units)
Table 16.137 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Type of Plastic
Table 16.138 Global Demand for Ethylene Vinyl Acetate Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.139 Global Demand for Polypropylene Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.140 Global Demand for Polyvinyl Chloride Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.141 Global Demand for Other Plastic Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.142 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Volume
Table 16.143 Global Demand for 0-250 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.144 Global Demand for 250-500 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.145 Global Demand for 500-1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.146 Global Demand for >1,000 mL Dual/Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
Table 16.147 Global Demand for Dual/Multi Chamber Infusion Bags, 2021-2030: Distribution by Geography
Table 16.148 Global Demand for Dual/Multi Chamber Infusion Bags in North America, 2021-2030 (Billion Units)
Table 16.149 Global Demand for Dual/Multi Chamber Infusion Bags in Europe, 2021-2030 (Billion Units)
Table 16.150 Global Demand for Dual/Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030 (Billion Units)
Table 16.151 Global Demand for Dual/Multi Chamber Infusion Bags in Latin America, 2021-2030 (Billion Units)
Table 16.152 Global Demand for Dual/Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030 (Billion Units)
Table 16.153 Global Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.154 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
Table 16.155 Dual Chamber Prefilled Syringes Market for Liquid/Powder Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.156 Dual Chamber Prefilled Syringes Market for Liquid/Liquid Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.157 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used (USD Billion)
Table 16.158 Glass Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.159 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.160 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume (USD Billion)
Table 16.161 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.162 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.163 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.164 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.165 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography (USD Billion)
Table 16.166 Dual Chamber Prefilled Syringes Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.167 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.168 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.169 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.170 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.171 Global Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.172 Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
Table 16.173 Dual Chamber Cartridges Market for Liquid/Powder Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.174 Dual Chamber Cartridges Market for Liquid/Liquid Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.175 Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used (USD Billion)
Table 16.176 Glass Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.177 Plastic Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.178 Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume (USD Billion)
Table 16.179 Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.180 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.181 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.182 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.183 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography (USD Billion)
Table 16.184 Dual Chamber Cartridges Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.185 Dual Chamber Cartridges Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.186 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.187 Dual Chamber Cartridges Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.188 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.189 Dual Chamber Cartridges Market in Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.190 Global Dual/Multi Chamber Infusion Bags Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.191 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
Table 16.192 Dual/Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.193 Dual/Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.194 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic (USD Billion)
Table 16.195 Dual/Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.196 Dual/Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.197 Dual/Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.198 Dual/Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.199 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume (USD Billion)
Table 16.200 Dual/Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.201 Dual/Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.202 Dual/Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.203 Dual/Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.204 Dual/Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography (USD Billion)
Table 16.205 Dual/Multi Chamber Infusion Bags Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.206 Dual/Multi Chamber Infusion Bags Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.207 Dual/Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.208 Dual/Multi Chamber Infusion Bags Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 16.209 Dual/Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Note: Product cover images may vary from those shown
  • 3M Innovative Properties
  • AbbVie
  • Ablynx
  • Acacia Pharma
  • Acadia Pharmaceuticals
  • AcelRx Pharmaceuticals
  • Achaogen
  • Acorda Therapeutics
  • Actelion Pharmaceuticals
  • ADC Therapeutics
  • ADIENNE
  • Advanced Accelerator Applications (AAA)
  • AdvoCare Medical
  • Aerie Pharmaceuticals
  • Agios Pharmaceuticals
  • Aguettant
  • AkaRx (acquired by Eisai)
  • Akcea Therapeutics (acquired by Ionis Pharmaceuticals)
  • Alcon Laboratories
  • Alexion Pharmaceuticals
  • Alkermes
  • Allergan
  • Almirall
  • Alnylam Pharmaceuticals
  • AMAG Pharmaceuticals (acquired by Covis Pharma)
  • Amgen
  • Amivas
  • Amphastar Pharmaceuticals
  • Amsino
  • Anacor Pharmaceuticals (acquired by Pfizer)
  • Antares Pharma
  • Apellis Pharmaceuticals
  • Aquestive Therapeutics
  • ARaymond
  • Ardelyx
  • ARIAD Pharmaceuticals (acquired by Takeda)
  • Array BioPharma (acquired by Takeda)
  • Arte
  • Astellas Pharma
  • AstraZeneca
  • Aurinia Pharmaceuticals
  • AVEO Pharmaceuticals
  • B. Braun
  • Bausch & Lomb
  • Bausch Health Companies (formerly Valeant Pharmaceuticals)
  • Baxter
  • Bayer Healthcare
  • Becton Dickinson (BD)
  • BeiGene
  • Biocorp
  • BioCryst Pharmaceuticals
  • Biogen
  • Biohaven Pharmaceuticals
  • BioMarin Pharmaceutical
  • Bioprojet Pharma
  • BloodWorks
  • Blue Earth
  • Blueprint Medicines
  • Boehringer Ingelheim
  • Bracco Diagnostics
  • Braintree Laboratories  (acquired by Sebela Pharmaceuticals )
  • Bristol Myers Squibb
  • Cassiopea
  • Catalyst Pharmaceuticals 
  • Celgene
  • Celltrion 
  • Chelsea Therapeutics
  • Chemo Research
  • Chiesi USA
  • Cleveland Cord Blood Center (CCBC)
  • CLINUVEL
  • Clovis Oncology
  • Cosmo Pharmaceuticals
  • Credence Medsystems
  • Cubist Pharmaceuticals
  • Curium
  • Daiichi Sankyo
  • Debiotech
  • Deciphera Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Duoject
  • Durata Therapeutics (acquired by Actavis)
  • Dutch Ophthalmic Research Center
  • Eiger BioPharmaceuticals
  • Eisai
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Enable Injections
  • Epizyme
  • Equashield
  • Esperion Therapeutics
  • Evolus
  • ExEm Foam
  • EyePoint Pharmaceuticals
  • Ferrer
  • Fresenius Kabi
  • G1 Therapeutics
  • Galderma
  • Genentech
  • Gerresheimer
  • Gilead Sciences
  • GlaxoSmithKline
  • Global Blood Therapeutics
  • Greenwich Biosciences
  • Grifols
  • Haemopharm
  • Harmony Biosciences
  • Helapet
  • Helsinn Healthcare
  • Hemedis
  • Horizon Therapeutics
  • ICU Medical
  • IDEO
  • iHealthNet
  • Immunomedics (acquired by Gilead Sciences)
  • Incyte
  • Insmed
  • Integrity Bio
  • Intercept Pharmaceuticals
  • Intra-Cellular Therapies
  • Ionis Pharmaceuticals
  • Ironwood Pharmaceuticals
  • ITF Pharma
  • Janssen Pharmaceuticals
  • Jazz Pharmaceuticals
  • JW Chemi Town
  • KAI Pharmaceuticals (acquired by Amgen)
  • Kapsam
  • Karyopharm Therapeutics
  • KemPharm
  • Kite Pharma
  • Kyowa Kirin
  • Kythera Biopharma (acquired by Allergan)
  • La Jolla Pharmaceutical Company
  • Leadiant Biosciences
  • Lexicon Pharmaceuticals
  • Lundbeck
  • Lupin
  • MacroGenics
  • Maeda Industry
  • Mayne Pharma 
  • MEDIPHARMAPLAN
  • Medicines Development for Global Health (MDGH)
  • MedXL 
  • Melinta Therapeutics
  • Merck
  • Millennium Pharmaceuticals (acquired by Takeda)
  • Miltenyi Biotec
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Myovant Sciences
  • Mystic Pharmaceuticals
  • Nabriva Therapeutics
  • Neurocrine Biosciences
  • Nipro
  • Novartis
  • Novimmune
  • Novo Nordisk
  • NPS Pharmaceuticals
  • NS Pharma
  • Nündel Kunststofftechnologie
  • Ocular Therapeutix
  • Oncopeptides
  • Organon International
  • Origin Biosciences
  • Ortho Dermatologics
  • Otsuka Pharmaceutical
  • Paladin
  • Paratek Pharmaceuticals
  • Pfizer
  • PHC Injection Device Technologies
  • Piramal Imaging
  • Portola Pharmaceuticals (acquired by Alexion Pharmaceuticals)
  • Progenics Pharmaceuticals
  • PTC Therapeutics
  • Puma Biotechnology
  • QED Therapeutics
  • Radius Health
  • Recon Therapeutics
  • Recordati Rare Diseases
  • Regeneron Pharmaceuticals
  • Relypsa
  • Rempex Pharmaceuticals
  • Travere Therapeutics (formerly Retrophin)
  • Rhythm Pharmaceuticals
  • Ridgeback Biotherapeutics
  • Rigel Pharmaceuticals
  • Roche
  • Sage Therapeutics
  • Sagentia Innovation
  • Sanofi
  • Sanofi Genzyme
  • Sarepta Therapeutics
  • SCHOTT
  • SCHOTT-KAISHA
  • SCYNEXIS
  • Seagen
  • Servier Pharmaceuticals
  • sfm medical devices
  • Shandong Pharmaceutical Glass
  • Shield Therapeutics
  • Shionogi
  • Shire Pharmaceuticals (acquired by Takeda)
  • SIGA Technologies
  • Simplivia
  • SIPPEX
  • SK Life Science
  • SKINSORB
  • Spark Therapeutics
  • Spectrum Pharmaceuticals
  • Sprout Pharmaceuticals
  • Stemline Therapeutics (acquired by Menarini)
  • Stevanato Group
  • Strongbridge Biopharma
  • Sun Pharma
  • Sun Pharma Advanced Research Company (SPARC)
  • Supernus Pharmaceuticals
  • SYMATESE DEVICE
  • Synergy Pharmaceuticals
  • Taian Youlyy Industrial
  • Taiho Oncology
  • TaiMed Biologics
  • Taisei Kako
  • Takeda Pharmaceuticals
  • Technoflex
  • Terumo
  • TESARO (acquired by GlaxoSmithKline)
  • Tetraphase Pharmaceuticals
  • Teva Pharmaceutical 
  • TG Therapeutics
  • The Conference Forum
  • The Feinstein Institutes for Medical Research 
  • The International Research Conference
  • The Medicines Company (acquired by Novartis)
  • The Metrix Company (formerly Riggs BioChemical)
  • TherapeuticsMD
  • Theravance Biopharma and Mylan
  • Trevena
  • Tyfill Pharmapack
  • U.S. Food and Drug Administration (USFDA)
  • UIHC – P E T Imaging Center
  • Ultragenyx Pharmaceutical
  • Unilife
  • UCB
  • United Therapeutics
  • Unitract Syringe
  • University of California, Los Angeles (UCLA)
  • Urovant Sciences
  • US WorldMeds
  • Valmed Pharma
  • VANDA Pharmaceuticals
  • Vanrx Pharmasystems
  • Verastem Oncology
  • Vericel
  • Vertex Pharmaceuticals
  • Vetter Pharma
  • Viela Bio (acquired by Horizon Therapeutics)
  • ViiV Healthcare
  • Vonlanthen
  • Vygon
  • Weibel CDS
  • Wellstat Therapeutics
  • West Pharmaceutical Services
  • Wyeth
  • Y-mAbs Therapeutics
  • Ypsomed
  • Yukon Medical
  • Zealand Pharma
  • Zionexa (acquired by GE Healthcare)
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...